Abstracts tagged "SLE"

Abstract Number: 84 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Estelle Gerossier ¹, Saba Nayar ², Charlotte Smith ², Sylvie Froidevaux ³, Francesca Barone ² and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, ²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ³Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
Abstract Number: 693 • 2019 ACR/ARP Annual Meeting
Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
Jessica English¹, Trevor Faith ², Dulaney Wilson ¹ and Diane Kamen ³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease of unknown etiology. Previous studies of beauty products as potential triggers of SLE development…
Abstract Number: 1141 • 2019 ACR/ARP Annual Meeting
Racial Disparities in Lupus Medication Adherence
Kai Sun¹, Amanda Eudy ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: Medication non-adherence is common among SLE patients and is disproportionately more frequent in underrepresented racial minorities. We examined adherence gaps between minority and Caucasian…
Abstract Number: 1601 • 2019 ACR/ARP Annual Meeting
Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus
Cynthia Matilda Wendo¹, George Oyoo ¹, Thomas Otieno Kwasa ¹, Marybeth Maritim ¹, Sybil Nakitare ² and Judith Kwasa ¹, ¹University of Nairobi, Nairobi, Kenya, ²Kenyatta National Hospital, Nairobi, Kenya
Background/Purpose: Peripheral neuropathy (PN), one of the neuropsychiatric syndromes of SLE, occurs in 2% to 36% of patients. It has been associated with high disease…
Abstract Number: 2276 • 2019 ACR/ARP Annual Meeting
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Ravyn Njagu¹, Amanda Eudy ², Amanda Snyderman ¹, Lisa Criscione-Schreiber ² and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: While centers have worked to optimize lupus pregnancy outcomes, additional efforts are required to have a broader impact on lupus pregnancy outcomes. The goal…
Abstract Number: 110 • 2019 ACR/ARP Annual Meeting
Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus
Rhea Bhargava¹, Michelle S. Lee ², Takayuki Katsuyama ³ and Vaishali R. Moulton ³, ¹Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from systemic lupus erythematosus (SLE) patients exhibit a hyperactive phenotype with defects in homeostasis, signaling and cytokine production. By discovery approaches, we…
Abstract Number: 701 • 2019 ACR/ARP Annual Meeting
Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis
Hiroshi Kajiyama¹, Hidekazu Ikeuchi ², Junya Suwa ², Daisuke Ikuma ³, Hiroyuki Kurosawa ⁴, Yoshiaki Hirayama ⁴, Masanori Hara ⁵, Yoshihisa Nojima ⁶, Keiju Hiromura ² and Toshihide Mimura ⁷, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Nerima, Tokyo, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gumma, Japan, ³Department of Rheumatology, Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan, ⁴Department of reagent research and development, Denka Seiken Co. Ltd., Gosen, Niigata, Japan, ⁵Iwamuro health promotion center, Iwamuro-onsen, Niigata, Japan, ⁶Gunma Rheumatology Clinic, Takasaki, Gumma, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Podocytes, glomerular visceral epithelial cells, function as molecular sieve not to filter high molecular weight proteins such as albumin and globulins. Various immunological insults…
Abstract Number: 1142 • 2019 ACR/ARP Annual Meeting
Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study
Kai Sun¹, Carrie Dombeck ¹, Teresa Swezey ¹, Amy Corneli ¹, Amanda Eudy ¹, Rebecca Sadun ¹, Jennifer Rogers ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: SLE disproportionately affects underrepresented racial minorities, groups that often have lower rates of medication adherence. This study aimed to explore barriers and facilitators of…
Abstract Number: 1612 • 2019 ACR/ARP Annual Meeting
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough ¹, Shane McKie ², Benjamin Parker ¹, Alan Jackson ³, Philip Pemberton ⁴, Rebecca Elliott ⁵ and Ian Bruce⁶, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²FBMH Platform Sciences, Enabling Technologies & Infrastructure, The University of Manchester, Manchester, United Kingdom, ³Wolfson Molecular Imaging Centre, Institute of imaging and bioinformatics, The University of Manchester, Manchester, United Kingdom, ⁴Manchester University NHS Foundation Trust, Manchester, ⁵Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, The University of Manchester; NIHR Manchester Biomedical Research Centre, Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) is a common symptom in systemic lupus erythematosus (SLE), that significantly affects quality of life but there are limited treatment options…
Abstract Number: 2519 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE
Daniel Strasser ¹, Virginie Sippel ¹, Ursula Grieder ¹, Andrea Kieninger-Graefitsch ², Gabin Pierlot ¹, Hervé Farine ¹, Paulina Kulig ¹, Geoffroy Bourquin ¹, Marcel Keller ¹, Peter Groenen ¹, Marten Trendelenburg ² and Mark Murphy¹, ¹Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, ²University Hospital Basel, Basel, Switzerland
Background/Purpose: SLE is an autoimmune disease driven by autoreactive T and B lymphocytes. Lymphocytes infiltrate self-antigen expressing tissues, in which tertiary lymphoid structures are often…
Abstract Number: 308 • 2019 ACR/ARP Annual Meeting
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Konrad Dziamski¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…
Abstract Number: 704 • 2019 ACR/ARP Annual Meeting
Improving Patient-Centered Care by Utilizing Lupus Wellness Program
Jacinta Renaldi¹, Fotios Koumpouras ¹, Lenore Buckley ¹ and Mei Xue Dong ¹, ¹Yale University, New Haven
Background/Purpose: Although the mortality rate of lupus has decreased with improvement of treatment options, it remains high compared to non-SLE mortality. The factors that contribute…
Abstract Number: 1148 • 2019 ACR/ARP Annual Meeting
Examining Five Year Lupus Retention in Care in an Academic Cohort
Christie Bartels¹ and Maria Schletzbaum ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: SLE often causes silent damage, making routine clinic and lab monitoring critical for detecting new manifestations or flares. The 2012 ACR nephritis guidelines recommended…
Abstract Number: 1620 • 2019 ACR/ARP Annual Meeting
T-cell Exhaustion in Prolonged Remission SLE Patients
Francisco Treviño-Tello¹, Guadalupe Lima ¹, Juan Jakez-Ocampo ², Luis Llorente ¹, Yemil Atisha-Fregoso ¹ and Hilda Fragoso-Loyo ³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: Cellular exhaustion is a cellular dysfunction characterized by the progressive loss of the effector function, and an increased expression of multiple inhibitory receptors. Exhaustion…
Abstract Number: 2520 • 2019 ACR/ARP Annual Meeting
Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Richard Furie¹, Darrin Bomba ², Maria Dall'Era ³, Amber Khan ⁴, Miguel Soneira ⁴, Janet Anderl ², Jinhai Wang ², Christopher Kirk ² and Niti Goel ⁵, ¹Northwell Health, Great Neck, NY, ²Kezar Life Sciences, SOUTH SAN FRANCISCO, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Accurate Clinical Research, Houston, TX, ⁵Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: Nonspecific proteasome inhibitors, eg, bortezomib (BTZ), target both the constitutive and immuno- proteasome and are approved for the treatment of multiple myeloma. While BTZ…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].